BC
VIR icon

Bridgefront Capital’s Vir Biotechnology VIR Stock Holding History

Bridgefront Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.4K Buy
+10,427
New +$83.1K 0.02% 501
2025
Q2 		– Sell
-28,205
Closed -$183K – 868
2025
Q1 		$183K Buy
+28,205
New +$251K 0.05% 533
2024
Q3 		– Sell
-15,751
Closed -$140K – 729
2024
Q2 		$140K Buy
+15,751
New +$151K 0.06% 437

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bridgefront Capital's VIR Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Vir Biotechnology (VIR) in Q1 2026: 10,427 shares worth $93.4K. The stake represents 0.02% of the portfolio and ranks #501 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in VIR as recently as Q1 2025.

Bridgefront Capital first reported a position in VIR in Q2 2024 and has held it in 3 quarters since. The position peaked at $183K in Q1 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Bridgefront Capital held 10,427 shares of Vir Biotechnology worth $93.4K as of Q1 2026.
  • Vir Biotechnology was a new Bridgefront Capital position in Q1 2026.
  • Vir Biotechnology made up 0.02% of Bridgefront Capital's portfolio in Q1 2026, its #501 holding.
  • Bridgefront Capital first reported a position in Vir Biotechnology in Q2 2024 and has held it in 3 quarters since.
  • Bridgefront Capital's Vir Biotechnology position peaked at $183K in Q1 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.